The MoneyShow Income, Growth, & Value Virtual Expo will be held from April 29-30, 2025, as a virtual event. The online conference features the financial industry’s brightest minds sharing their wisdom and advice. Attendees can connect with them during the LIVE presentations and get their queries solved.

The MoneyShow Virtual Expo will show investors how they can both safeguard and grow their portfolios. Attendees can directly chat with distinguished experts to learn pro tips on creating a strong and diverse portfolio. The MoneyShow organization brings in 44 years of industry experience offering traders and investors sound financial and trading advice, resources, and collaboration opportunities to enable them to build their wealth.

Whether you’re a seasoned investor or a newcomer, you won’t want to miss the event.

Top Reasons to Attend:

• Gain valuable insights from top financial experts.
• Learn about income-generating investments, growth opportunities, and value-based strategies.
• Network with like-minded investors and traders.
• Learn about key market trends and make informed investment decisions.

From growth-stage to veteran companies, several players will showcase their products, services, and investment opportunities. Experts will offer live market analysis and sound recommendations on many investment topics. Attendees can connect with industry experts, investors, and peers to explore new investment opportunities and expand their horizons.

Attendees will also have access to interactive, virtual booths that offer message boards, research data, educational videos, phenomenal discounts, and other valuable information. To top it all off, the event provides a digital briefcase for attendees to assemble, download, and store all the collected information in one place.

To learn more, please visit https://ibn.fm/ofEPM.

• Soligenix is enrolling patients in its FLASH2 study, with a formal interim analysis anticipated early in 2026.
• SNGX’s HyBryte is a novel photodynamic therapy using synthetic hypericin activated by safe visible light.
• The ongoing phase 3 replication study meets stringent requirements of regulatory agencies to strengthen the case for HyBryte as a commercially available treatment.

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases and unmet medical needs, is making significant strides in its efforts to bring innovative therapies to patients with early-stage cutaneous T-cell lymphoma (“CTCL”). The company’s lead candidate, HyBryte(TM) (“SGX301”), has already demonstrated positive results in a prior phase 3 trial, and Soligenix is now conducting a phase 3 replication study to further validate its efficacy and safety (https://ibn.fm/zdRnQ). This development marks an important milestone in the company’s mission to address an urgent medical need in a condition with limited treatment options.

“We are pleased to be initiating patient enrollment into our FLASH2 study,” said Soligenix president and CEO Christopher J. Schaber (https://ibn.fm/LjfXu). “FLASH2 is expected to enroll patients in the United States and Europe, with a formal interim analysis anticipated early in 2026. Given the extensive engagement with the CTCL community, the esteemed Medical Advisory Boards in the U.S. and Europe, key patient advocacy groups like the Cutaneous Lymphoma Foundation, as well as our previous trial experience with this disease, accelerated enrollment in support of this study is anticipated. We look forward to providing periodic updates on the trial’s progress in 2025.”

CTCL is a rare and chronic form of non-Hodgkin’s lymphoma that primarily affects the skin, leading to symptoms such as red, scaly patches, growths and severe itching (https://ibn.fm/JXiDN). Patients with early-stage CTCL often struggle to find effective treatments that are both safe and well-tolerated over long periods. Current treatment options include corticosteroids, phototherapy and chemotherapy. These treatments often come with limitations, such as toxicity, inconsistent responses and adverse side effects.

HyBryte(TM) is a novel photodynamic therapy using synthetic hypericin activated by safe visible light. This revolutionary treatment offers a potentially game-changing approach by providing a noninvasive, well-tolerated alternative that targets malignant T-cells with precision.

The initial phase 3 trial (“FLASH”) of HyBryte(TM) showed strong efficacy, demonstrating a statistically significant response in patients compared to placebo. The study results indicated that HyBryte(TM) was not only effective in reducing lesion size and severity but also presented a favorable safety profile, making it a compelling option for long-term disease management. The positive data from this initial trial has led Soligenix to move forward with the FLASH2 replication study, which aims to confirm the results in a larger patient population and further establish HyBryte(TM) as a viable front-line treatment for early-stage CTCL.

The ongoing phase 3 replication study is designed to potentially meet the stringent requirements of regulatory agencies, in order to strengthen the case for HyBryte(TM) as a commercially available treatment. If successful, this study could pave the way for regulatory approval worldwide, bringing a much-needed new option to patients who have long been underserved by existing therapies. The ability of HyBryte(TM) to deliver effective results with minimal systemic exposure makes it particularly well-suited for chronic conditions such as CTCL, where long-term management is essential.

Soligenix is positioning itself as a leader in the rare disease space by focusing on therapies that address critical gaps in treatment. In addition to HyBryte(TM), the company has a diversified pipeline that includes other promising candidates targeting conditions such as oral mucositis, and Behcet’s Disease, as well as mild-to-moderate psoriasis. By leveraging its proprietary drug development expertise and commitment to scientific rigor, Soligenix is working to bring life-changing treatments to patients who have few, if any, safe and effective therapeutic alternatives.

The significance of Soligenix’s phase 3 replication study extends beyond just the CTCL community. Success in this trial could reinforce the company’s broader strategy of using innovative therapeutic approaches to tackle rare and difficult-to-treat diseases. The progress of HyBryte(TM) also highlights the importance of photodynamic therapy as a novel and effective modality that could potentially be applied to other dermatological and oncological conditions.

As Soligenix moves forward with its pivotal phase 3 replication study, industry observers, investors, and medical professionals will be closely monitoring the results. A positive outcome could not only validate HyBryte(TM) as a groundbreaking treatment for early-stage CTCL but also elevate Soligenix’s standing as a leader in the rare-disease treatment space. The company remains dedicated to advancing its research and bringing new hope to patients facing life-altering conditions with limited treatment options.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• Solving the ongoing hospitality labor crisis can create billion-dollar companies
• Nightfood’s unique RaaS business model lowers barriers to entry while maximizing revenue per client
• Nightfood’s subsidiaries Skytech and Future Hospitality Ventures (RoboOp365) provide breakthrough RaaS solutions for both front and back of house

The hospitality industry is undergoing a radical transformation as automation promises to forever change the hotel labor landscape. With the rapid evolution of AI, robotics has undergone a seismic change. No longer an expensive novelty that delivered little value to hotel operators, robotics is becoming a must-have to remain in business and compete.

Combining the most advanced AI-driven robotics technology with its unique Robots-as-a-Service (“RaaS”) financial model, Nightfood Holdings (OTCQB: NGTF) is poised to lead the hospitality industry into the robotics age.

From mobile check-ins and digital room keys to online concierge services and smart room features, technology enables hotels to provide seamless experiences for both guests and staff. This not only boosts customer satisfaction but also improves operational efficiency by automating repetitive tasks and optimizing resource management. As we’ve seen in the past, falling behind on tech can be fatal.

This means the entire industry will be racing to adopt AI-driven robotics in the next one to three years. This is not optional.

As a leader hospitality tech, NGTF’s unique RaaS business model is a key differentiator investors should consider when placing their sector bets. RaaS allows hotel operators to quickly and easily incorporate mission-critical robotics without massive upfront capital expenditures.

Instead of having to purchase robotics upfront and then coordinate all elements of integration and maintenance, hotel operators can lease their robotics tech through NGTF. By doing this, a hotel can seamlessly integrate robotics into their operations with a simple line-item expense on their income statement. NGTF subsidiaries provide setup, installation, integration, training, and maintenance.

The benefits to NGTF are equally as powerful. Because RaaS significantly lowers barriers to entry, adoption rates go up and customer acquisition costs go down. The leases increase client satisfaction and create a sticky and predictable revenue stream with exceptionally high retention rates and customer lifetime value.

As the tech evolves at breakneck pace, hotels can easily upgrade to the latest version without being stuck with out of date “last year’s model.”

NGTF subsidiaries Skytech and Future Hospitality Ventures can automate everything from cleaning linens and trash removal to food preparation and deliveries.

The service robotics market is projected to reach $107.75 billion by 2030 (ibn.fm/k7Skz). How much investor value will be created in coming years in this sector?

This presents an opportunity for forward-thinking investors who can see the critical role robotics will play in hospitality (ibn.fm/QdUHm).

Nightfood’s recent acquisition of Skytech Automated Solutions (ibn.fm/Cd3Le) is a major industry development. Skytech’s leadership team has decades of experience in hotel management, business operations, and technology-driven solutions.

Skytech is best known for its AI-driven Laundry Helper robot. Laundry Helper picks up and transports laundry and trash, reducing the burden on housekeeping staff. Equipped with advanced sensors, AI navigation, and robotic arms, it can operate elevators and open doors on its own, making it the perfect housekeeping assistant for hotels.

Already successfully deployed in its first properties from InterContinental Hotels Group and Hilton Worldwide Holdings, the Skytech team has its sights set on rapid industry expansion for Laundry Helper, as well as its Concierge, Matradee, and Sweeper robots.

Synergies can be expected between these offerings and the food prep and delivery bots provided by NGTF subsidiary Future Hospitality, allowing hotel operators to procure all their RaaS needs through Nightfood Holdings.

The industry is at a tipping point. In a few years, hotels without integrated robotics will seem as antiquated as jingly keys, smoking rooms, and in-room VCRs.

NGTF is leading the way.

For more information, visit the company’s website at NightfoodHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

Quant Strats USA 2025, held on March 11 at Quorum by Convene in New York, brought together over 380 professionals in quantitative finance, with 70% of attendees representing the Buy-Side, including hedge funds, asset managers, and investment banks. The event reaffirmed its role as a premier forum for exploring advancements in artificial intelligence (“AI”), machine learning (“ML”), and large language models (“LLMs”) within finance, offering attendees unparalleled access to industry-leading insights and networking opportunities.

The conference featured over 50 expert speakers who examined how AI and ML are no longer just theoretical innovations but essential tools shaping investment strategies, risk management, and trade execution. AI & ML in Asset Management addressed how firms are integrating advanced algorithms into portfolio construction, risk assessment, and trade execution to drive efficiency and improve returns. The Future of Large Language Models (“LLMs”) in Quant Finance explored how LLMs are being leveraged for predictive modeling, sentiment analysis, and automating complex financial decision-making. The discussion underscored the increasing reliance on AI-driven insights to navigate evolving market conditions and improve performance.

A central theme throughout the event was the growing synergy between quantitative and fundamental investment strategies. Blending Quant & Fundamental Strategies featured leading portfolio managers and quant strategists who discussed the complexities of combining data-driven models with traditional financial analysis, highlighting the benefits and challenges of hybrid approaches. Meanwhile, Alternative Data & Alpha Generation explored how non-traditional data sources, ranging from satellite imagery to consumer transaction data, are unlocking new opportunities for alpha generation, providing firms with an edge in systematic trading.

With the rapid evolution of electronic trading, High-Frequency Trading & Execution Algorithms took a deep dive into the latest advancements in trade execution, latency reduction, and market-making strategies. The session provided a comprehensive look at how firms are optimizing execution in an increasingly automated environment. Meanwhile, Risk Management in a Volatile Market tackled the challenges of adapting quant strategies to turbulent market conditions, emphasizing the importance of robust risk frameworks in mitigating potential losses and ensuring long-term portfolio stability.

Beyond the content-rich sessions, Quant Strats USA 2025 offered extensive networking opportunities, allowing attendees to connect with top-tier data scientists, quantitative analysts, institutional investors, and technology providers. The event’s focus on practitioner-led discussions ensured that participants left with actionable takeaways, equipping them with cutting-edge tools and strategies to navigate the evolving landscape of quantitative finance.

The discussions and insights from Quant Strats USA 2025 will continue later this year at Quant Strats Europe, offering another opportunity for professionals to engage with global leaders in the field. As AI and ML continue to drive transformation in quantitative finance, staying ahead of these developments is crucial. Attendees of Quant Strats Europe can expect in-depth discussions on the latest trends, hands-on workshops, and expanded networking opportunities designed to help firms remain competitive in an increasingly data-driven industry. For more details and to secure participation, visit Quant Strats Europe.

• The company will present at the Jones Las Vegas Technology and Innovation Conference on April 8-9, to update investors on its lead drug candidate.
• The conference will provide one-on-one meetings and networking opportunities for institutional investors and executives.
• Clene recently received FDA guidance on a potential accelerated approval pathway for CNM-Au8 in ALS treatment.
• New analyses suggest CNM-Au8 improves survival for ALS patients, with a 4.1-month increase in restricted mean survival time.
• Clene plans to begin enrollment for a Phase 3 confirmatory trial (RESTORE-ALS) in mid-2025.

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), will participate in the upcoming Jones Las Vegas Technology and Innovation Conference at The Venetian Resort. The April 8-9 event, organized by JonesTrading and supported by B2i Digital, provides a platform for direct engagement between innovative companies and institutional investors (https://ibn.fm/fIKDc).

“We look forward to participating in the Jones Conference, which provides an opportunity to share our progress and connect directly with investors in a setting that fosters productive conversations,” said Rob Etherington, CEO and President of Clene.

The conference will feature keynote addresses from Dr. Charity Dean, CEO of PHC Global, and Eric F. Trump, Executive Vice President of The Trump Organization, along with a Jones-hosted Golf Event and Cocktail Reception.

Commenting on the event, Alan Hill, CEO of JonesTrading, underlined that his firm and the conference are focused on creating a forum where public companies can communicate directly with the investment community, while B2i Digital, Inc. CEO David Shapiro underlined his company’s commitment to ensuring that companies participating in the Jones Conference have a platform to reach investors who are actively seeking new ideas and opportunities.

Clene’s presence at the Jones Conference offers investors a chance to engage with the company at a pivotal moment in its regulatory journey. At the event, the company will provide key updates about its lead drug candidate CNM-Au8 and its path to regulatory approval. CNM-Au8 is an oral suspension of gold nanocrystals designed to improve cellular energy production and utilization, which is critical for maintaining neuronal health. In several clinical trials, the drug candidate has been shown to improve survival rates in ALS patients, a finding supported by preclinical evidence that the drug works by improving central nervous system cells’ survival and function. The company recently received FDA guidance on using biomarker data to support an accelerated approval pathway for the drug.

Following a November 2024 meeting with the FDA’s Division of Neurology 1 (“DN1”), Clene was advised to analyze additional data from ongoing Expanded Access Programs (“EAPs”) to evaluate CNM-Au8’s impact on neurofilament light chain (“NfL”), a potential surrogate endpoint for ALS treatment. No significant safety concerns have emerged in over 800 patient years of CNM-Au8 use, and no serious adverse events (“SAEs”) have been linked to the treatment.

Clene expects to finalize a statistical analysis plan with the FDA in Q2 2025 before collecting and analyzing NfL biomarker data in Q3 2025, supporting a potential NDA submission in the second half of 2025.

New survival analyses compared CNM-Au8 (30 mg, Regimen C) against a concurrent control group (Regimen A) in the HEALEY ALS Platform Trial. Findings include:

• A 4.1-month improvement in restricted mean survival time (“RMST”) (p=0.045).
• Enhanced survival in severe ALS cases, with median survival extended by 11.9 months.
• A 44% decrease in mortality risk for patients with high baseline NfL levels (p=0.006).

To further evaluate CNM-Au8’s efficacy, Clene will launch the Phase 3 RESTORE-ALS trial in mid-2025. The study will assess overall survival as a primary endpoint and delayed ALS clinical worsening events as a secondary endpoint.

“We expect further regulatory guidance in 2025 on the critical next steps required to advance our CNM-Au8 NDA submission for the treatment of ALS under the accelerated approval pathway,” said Etherington. The company also continues to evaluate CNM-Au8’s impact on vision and cognition in multiple sclerosis patients, he added. “As always, we are incredibly motivated by our mission to help people suffering from ALS and other neurodegenerative diseases prolong their lifespan and improve their quality of life.”

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

The ZJ Alternative Products Expo will be held from April 3-5, 2025, at the Mana Wynwood Convention Center in Miami. The expo showcases the latest trends and the finest products and services of the counterculture community, tapping a worldwide audience. With Miami emerging as the epicenter of flavors, cultures, and smoke shops, the event aims to blend the local flavor of Florida with the rest of America.

ZJ Events organizes networking events by compiling valuable data on alternative products and presenting to leading brands, manufacturers, and dealers. They provide the counterculture community with a robust platform for exciting learning and business experiences in a safe and conducive environment. For the first time, the expo will offer B2B experience at the Alternative Products Expo.

The Alternative Products Expo offers unique experiences where local and global traders can network, strike deals, and learn about new innovations. Veterans and newcomers showcase exciting trends and products on the exhibition floor. The eclectic vibe, top-tier smoke shops, culinary adventures, vibrant nightlife, and confluence of cultures offer attendees an unforgettable experience.

Investors and enthusiasts can discover new avenues of business and opportunities, with immense new talent from the counterculture spectrum making a foray at the expo. The Alternative Products Expo in Miami offers business opportunities for newbies as well as veterans of the local smoke-shop community to expand their reach to global frontiers. Businesses and traders can network and connect on the event floor, fostering long-term relationships.

The attendees list consists of consumers, businesses, and enthusiasts from the local and international counterculture community. They not only come to discover new industry trends and products; they also enjoy the buzz and vibe of the Alternative Products market.

To learn more, please visit https://ibn.fm/TbO4J.

• SolarBank announced the sale of a 3.26 MW Camillus Solar Project to Solar Advocate Development LLC.
• The project will be built on a closed landfill and provide renewable energy to local subscribers.
• The project was awarded $1.06M in state incentives awarded under the NY-Sun Program.
• This marks the eighth project SolarBank has developed for Solar Advocate since 2018, and is the latest in a series of recent solar projects and battery storage systems the company has been developing.

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., has announced the sale and related construction contract for the 3.26 MW Camillus Solar Project for Solar Advocate Development LLC in a deal valued at $7.3 million USD (https://ibn.fm/qFjN7).

The project, located on a closed landfill site in Camillus, Onondaga County, New York, will operate as a community solar installation, allowing local residents and businesses to subscribe and receive credits on their utility bills for using renewable energy.

SolarBank has begun engineering and initial construction of the project and is working under an engineering, procurement, and construction (“EPC”) agreement dated March 18, 2025. The company has secured solar panels, inverters, racking, and transformers through partnerships with Tier 1 suppliers, ensuring the project stays on track.

Commenting on the deal, Dr. Richard Lu, CEO of SolarBank, explained that this was the eighth community solar project that will be constructed and operated for Solar Advocate as part of a relationship that originated in 2018. “The fact that they are a repeat customer is a testament to SolarBank’s ability to deliver projects and create long term sustainable value for its partners,” Dr. Lu added. “We continue to execute on our strategy of growth in the EPC segment of the business and the Independent Power Producer segment of the business.”

The company also announced that the New York State Energy Research and Development Authority (“NYSERDA”) has approved a $1,058,616 USD incentive for the project under the NY-Sun Program, which supports the expansion of solar energy in the state (https://ibn.fm/6qct4).

The incentive is contingent on the project’s completion within 30 months of approval. However, it does not increase the financial terms of the transaction with Solar Advocate. SolarBank has secured the necessary interconnection agreements with the local utility and obtained the required permits from regulatory authorities.

“SolarBank has a long-standing successful track record in working with government agencies in the United States and Canada to obtain government support and incentives for its clean and renewable energy projects,” Dr. Lu added. “While the Camillus Project has been sold to Solar Advocate, the receipt of these incentives further demonstrates SolarBank’s ability to execute and provide sustainable projects with robust financial returns.”

As construction moves forward, SolarBank continues to expand its presence in the EPC and independent power production markets, reinforcing its position in the growing community solar sector. With a development pipeline exceeding one gigawatt, the company aims to accelerate its growth in the renewable energy sector by continuously bringing new solar projects online.

The company recently announced a partnership with Viridi, an industry leader in fail-safe battery energy storage systems, to develop a combined 3.06 megawatt (“MW”) direct current ground-mounted solar power project and a 1.2 megawatt-hour (“MWh”) BESS in Buffalo, New York. Additionally, SolarBank is building three large-scale battery energy storage systems – two in Ontario and one in New York. As demand for renewable energy grows, SolarBank’s expansion into community solar projects positions the company as a key player in the transition to clean energy.

For more information, visit the company’s website at SolarBankCorp.com.

This report contains forward looking information. Please refer to the press releases entitled “$7.3 million USD Transaction Entered into with Solar Advocate Development LLC for the Sale and Construction of the Camillus Solar Project” and “SolarBank Partners with Viridi on Combined 3.06 MW Solar and 1.2 MWH Battery Energy Storage Project Located in Buffalo, New York” for additional details on the statements and related assumptions and risks.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

The MoneyShow Masters Symposium will be held in Dallas from April 4 to 5, 2025, and it will be an exclusive event that brings together high-net-worth investors and top experts in the field of finance. This two-day symposium will provide a robust platform for investors to learn from world-renowned fundamental and technical analysts, professional traders, and global market strategists.

MoneyShow has been working with traders and investors for the last 44 years, guiding and providing them with optimal resources to maximize their profits. MoneyShow hosts networking events where financial wizards help traders and investors to safeguard and strengthen their portfolios.

The Symposium will feature several sessions, including discussions on market trends, investment strategies, and opportunities in various asset classes. Attendees can evaluate their requirements based on the points discussed by the experts and learn fresh approaches to building optimal portfolios.

Industry leaders will share experiences and insights, providing investors with valuable information to enhance their investment portfolios. This event is a must-attend for investors concerned about the potential of a new bear market.

The MoneyShow Masters Symposium is not just a learning opportunity, but also a networking one. Attendees can connect with experts and other investors to share their ideas and gain new perspectives. The conference offers a great avenue for investors seeking to strengthen their investment portfolios and learn ways to add dynamic asset classes into a portfolio for a successful outcome.

To learn more, please visit https://ibn.fm/XTsOD.

The 5th PRC Performance Optimization Summit by DGE will be held in Philadelphia on April 29-30, 2025. DGE invites industry professionals to discuss compliance and the expertise needed to get the best regulatory results for advertising/promotional material.

The summit is hosted by Dynamic Global Events (“DGE”), a pioneer in organizing B2B events for life science companies. DGE offers the biopharma, healthcare, and medical device industries a robust forum for discussion, education, and collaboration.

Promotional review committees must be well-equipped in a rapidly evolving regulatory environment to stay abreast of the best practices for new technologies and platforms. Teams must listen to all voices and adapt to making necessary changes during the lifecycle of the drug.

The agenda of the PRC Performance Optimization Summit is to identify the biggest challenges and find winning execution strategies. Some of the topics include compliance with new CCN Dual Modality rules, managing review escalations, working with the Better Business Bureau, and grasping how AI impacts promotional review, to name a few. Experts will also conduct panel discussions about the tools to help reduce conflicts among team members.

Over two dozen speakers will share their invaluable insights that attendees can learn and understand to achieve the desired regulatory results. Industry veterans will also interact with the audience and solve their queries.

This important DGE event will focus on analyzing the best technical expertise to achieve regulatory compliance and meet deadlines across all media platforms. Participants looking to expand their network can leverage their reach by engaging with experts across the industry.

To learn more, please visit https://ibn.fm/3cdhG.

• The private credit sector is seeing remarkable growth with projections indicating that the market could surpass $1.5 trillion this year
• FAVO Capital has carved a niche for itself by recognizing the immense potential of alternative lending markets and private credit solutions
• The company’s approach to balancing risk and reward is built on a foundation of diversification and innovation

The financial landscape is rapidly evolving, with private credit and alternative lending markets emerging as key drivers of growth and innovation. As traditional banking institutions tighten their lending criteria and businesses seek more flexible financing solutions, the demand for alternative lending options, such as FAVO Capital (OTC: FAVO), continues to soar.

This shift is fueling remarkable growth in the private credit sector, with projections indicating that the market could surpass $1.5 trillion this year (https://ibn.fm/wTPRv). Alternative lending platforms, peer-to-peer financing and direct lending solutions are becoming increasingly attractive to both borrowers and investors, offering a unique blend of higher returns and diversification. FAVO Capital is at the forefront of this transformation, employing a strategic approach that balances risk and reward while capitalizing on high-growth opportunities in the alternative lending and fintech sectors.

FAVO Capital has carved a niche for itself by recognizing the immense potential of alternative lending markets and private credit solutions. With traditional lenders often unable to meet the needs of small and medium-sized enterprises (“SMEs”), alternative lending platforms have stepped in to bridge the gap, offering innovative financing options that cater to the diverse needs of businesses.

FAVO has strategically positioned itself to leverage these opportunities by investing in fintech platforms and alternative lending solutions that provide faster, more accessible, and technology-driven funding options (https://ibn.fm/B2XEd). Through a combination of rigorous due diligence, data-driven analysis and adaptive investment models, FAVO Capital constructs diversified portfolios that minimize exposure to risk while maximizing potential returns.

The alternative lending market is expected to continue its upward trajectory in 2025, driven by advances in fintech technology, growing demand for customized financing solutions and an increased appetite for nontraditional investments. As businesses seek capital outside of traditional banking channels, peer-to-peer lending, revenue-based financing and merchant cash advances have emerged as viable alternatives, each offering unique benefits to both lenders and borrowers. FAVO Capital’s investment strategy focuses on identifying and capitalizing on these opportunities, ensuring that its portfolio remains resilient in the face of market volatility.

FAVO Capital’s approach to balancing risk and reward is built on a foundation of diversification and innovation. By spreading investments across multiple sectors and industries, the company mitigates the impact of potential downturns in any single market segment. This diversified approach not only safeguards capital but also positions FAVO Capital to capitalize on emerging trends in high-growth sectors. Moreover, FAVO Capital leverages cutting-edge data analytics and intelligence models to continuously monitor market conditions and adjust its portfolios as needed. This adaptive strategy allows the company to respond swiftly to changing market dynamics, ensuring that its investments remain aligned with evolving opportunities and risks.

In the alternative lending space, fintech innovations are driving unprecedented efficiency and accessibility. Digital platforms are streamlining the loan application and approval processes, enabling faster decision-making and reducing administrative overhead. FAVO Capital recognizes the transformative potential of these technologies and has made strategic investments in fintech companies that are disrupting the traditional lending landscape. By supporting companies that harness the power of big data, machine learning and AI, FAVO Capital not only enhances the performance of its portfolio but also contributes to the growth and democratization of financial services.

Looking ahead, the outlook for private credit and alternative lending markets remains positive. As global economic uncertainties persist, investors are increasingly turning to private credit as a means of achieving higher yields and diversifying their portfolios. Alternative lending platforms, meanwhile, continue to fill the financing gap left by traditional banks, providing businesses with the capital they need to grow and thrive. FAVO Capital’s forward-thinking strategy positions it well to take advantage of these market trends, ensuring that its investors benefit from the growth of this dynamic sector.

For more information, visit the company’s website at FavoCapital.com.

NOTE TO INVESTORS: The latest news and updates relating to FAVO are available in the company’s newsroom at https://ibn.fm/FAVO